NVGND: 37.16% Up

January 4, 2012
Novogen Limited (NASDAQ:NVGND) opened the first trading session 2012 at $3.00 and set its new 52-high.
The trading tools registered the price change following the announcement that the company obtained a patent for treating cancer and tumors. The patent is expected to provide protection till September 2025.
The trading closed at $2.75 and the price change resulted in the decreasing trading volume of 2,463.00 which is almost ten times lower than its 30-day average. Over the recent year the company’s shares traded as low as $0.08. At the recently set price the company’s market capitalization stands at $8.19 million.
Novogen Limited is engaged in Biotechnology and Drugs industry of the Healthcare sector. The company is focused on pharmaceutical research and development, especially in the field of oncology.
 
By Brent Cole

Post new comment